RISANKIZUMAB

risankizumab 150 mg/mL injection, 1 mL pen device

RISANKIZUMAB (14713J)

risankizumab 150 mg/mL injection, 1 mL pen device
14713J
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Continuing treatment

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Continuing treatment - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 1 DPMQ: $5,140.26 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Skyrizi